{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:20Z","timestamp":1788306560848,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40121-023-00903-0","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T17:02:07Z","timestamp":1708102927000},"page":"481-499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands\u2014a  Holistic Approach"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-4172","authenticated-orcid":false,"given":"Florian","family":"Zeevat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6656-4472","authenticated-orcid":false,"given":"Joost J. M.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-5993","authenticated-orcid":false,"given":"Tjalke A.","family":"Westra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3972-9697","authenticated-orcid":false,"given":"Jan C.","family":"Wilschut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2695-5863","authenticated-orcid":false,"given":"Nina M.","family":"van Sorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-2638","authenticated-orcid":false,"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-3653","authenticated-orcid":false,"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"903_CR1","unstructured":"European Centre for Disease Prevention and Control. Factsheet about meningococcal disease 2019. Available from: https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/factsheet. (accessed on: Oct 26, 2021)"},{"issue":"4","key":"903_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, M\u00fcller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421\u201338.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"903_CR3","doi-asserted-by":"publisher","first-page":"e1099","DOI":"10.1093\/cid\/ciaa1774","volume":"73","author":"DLH Koelman","year":"2021","unstructured":"Koelman DLH, van Kassel MN, Bijlsma MW, Brouwer MC, van de Beek D, van der Ende A. Changing epidemiology of bacterial meningitis since introduction of conjugate vaccines: 3 decades of national meningitis surveillance in The Netherlands. Clin Infect Dis. 2021;73(5):e1099\u2013107.","journal-title":"Clin Infect Dis"},{"key":"903_CR4","unstructured":"Control ECfDPa. Invasive meningococcal disease. Annual epidemiological report for 2017. 2016. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2017-invasive-meningococcal-disease.pdf. (accessed on: Jan 25, 2022)"},{"key":"903_CR5","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800245","author":"M Krone","year":"2019","unstructured":"Krone M, Gray S, Abad R, et\u00a0al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.14.1800245.","journal-title":"Euro Surveill"},{"key":"903_CR6","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu Ministerie van Volksgezondheid WeS. Meningokokken ACWY-vaccinatie 2021. Available from: https:\/\/www.rivm.nl\/meningokokken\/meningokokken-acwy-vaccinatie. (accessed on: Jan 25, 2022)"},{"key":"903_CR7","unstructured":"Netherlands HCot. Executive summary. Vaccination against meningococcal disease 2018. Available from: https:\/\/www.healthcouncil.nl\/documents\/advisory-reports\/2018\/12\/19\/vaccination-against-meningococcal-disease. (accessed on: Oct 26, 2021)"},{"key":"903_CR8","unstructured":"Gezondheidsraad. De staatssecretaris van de Volksgezondheid WeS. Vaccinatie tegen meningokokken B: update 2022. Available from: https:\/\/www.gezondheidsraad.nl\/binaries\/gezondheidsraad\/documenten\/adviezen\/2022\/10\/12\/advies-vaccinatie-tegen-meningokokken-b-update\/advies-Vaccinatie-tegen-MenB_update.pdf. (accessed on: Jun, 2023)"},{"issue":"21","key":"903_CR9","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1001\/jama.2020.20449","volume":"324","author":"FMP Rodrigues","year":"2020","unstructured":"Rodrigues FMP, Marlow R, Sim\u00f5es MJ, Danon L, Ladhani S, Finn A. Association of use of a meningococcus Group B vaccine with Group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324(21):2187\u201394.","journal-title":"JAMA"},{"key":"903_CR10","unstructured":"Rodrigues FMP, editor Protocol summary: case-control study to evaluate the effetiveness of 4CMenB vaccine in the prevention of invasive meningococcal disease in Portugal 15th European Meningococcal and Haemophilus Disease Society (EMGM) Congress; 2019; Lisbon, Portugal."},{"issue":"1","key":"903_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jinf.2021.04.031","volume":"83","author":"F Martin\u00f3n-Torres","year":"2021","unstructured":"Martin\u00f3n-Torres F, Banzhoff A, Azzari C, et\u00a0al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect. 2021;83(1):17\u201326.","journal-title":"J Infect"},{"issue":"5","key":"903_CR12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.4161\/hv.23888","volume":"9","author":"KB Pouwels","year":"2013","unstructured":"Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GPJM, Postma MJ. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother. 2013;9(5):1129\u201338.","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"903_CR13","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/cid\/civ506","volume":"61","author":"SP Stoof","year":"2015","unstructured":"Stoof SP, Rodenburg GD, Knol MJ, et\u00a0al. Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: a subjective role for serogroup and clonal complex. Clin Infect Dis. 2015;61(8):1281\u201392.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"903_CR14","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.vaccine.2019.01.013","volume":"37","author":"S Scholz","year":"2019","unstructured":"Scholz S, Koerber F, Meszaros K, et\u00a0al. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37(12):1692\u2013701.","journal-title":"Vaccine"},{"key":"903_CR15","unstructured":"Statline CBvdSC. Consumentenprijzen; prijsindex 2015=100 2021. Available from: https:\/\/statline.cbs.nl\/Statweb\/publication\/?DM=SLNL&PA=83131NED. (accessed on: Oct 21, 2021)"},{"key":"903_CR16","unstructured":"Hakkaart-van Roijen L, van der Linden, N., Bouwmans, C., Kanters, T., Tan, S.S. Institute for Medical Technology Assessment. Erasmus Universiteit Rotterdam. Costing manual: Methodology of costing research and reference prices for economic evaluations in healthcare [in Dutch: Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg] 2016. Available from: https:\/\/www.zorginstituutnederland.nl\/over-ons\/publicaties\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg. (accessed on: Oct 26, 2021)"},{"key":"903_CR17","unstructured":"StatLine. Population; sex, age and marital status, 1st January [in Dutch: Bevolking; geslacht, leeftijd en burgerlijke staat, 1 januari] 2021. Available from: https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/7461BEV\/table?fromstatweb. (accessed on: Oct 26, 2021)"},{"issue":"10","key":"903_CR18","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1093\/cid\/ciz578","volume":"70","author":"AD Loenenbach","year":"2020","unstructured":"Loenenbach AD, van der Ende A, de Melker HE, Sanders EAM, Knol MJ. The clinical picture and severity of invasive meningococcal disease serogroup W compared with other serogroups in the Netherlands, 2015\u20132018. Clin Infect Dis. 2020;70(10):2036\u201344.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"903_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.vaccine.2004.06.019","volume":"23","author":"R Welte","year":"2004","unstructured":"Welte R, van den Dobbelsteen G, Bos JM, et\u00a0al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine. 2004;23(4):470\u20139.","journal-title":"Vaccine"},{"issue":"1\u20132","key":"903_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0264-410X(01)00254-7","volume":"20","author":"JM Bos","year":"2001","unstructured":"Bos JM, R\u00fcmke HC, Welte R, Postma MJ, Jager JC. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine. 2001;20(1\u20132):202\u20137.","journal-title":"Vaccine"},{"key":"903_CR21","unstructured":"Steunpunt Passend Onderwijs. Nieuwe versies bekostigingen (v)so, residenti\u00eble leerlingen, swv po en vo, kosten kortdurend verblijf, spelregels en toelichting Kijkdozen 2020. Available from: https:\/\/www.steunpuntpassendonderwijs-povo.nl\/document\/versies-bekostigingen-vso-residentiele-leerlingen-swv-po-en-vo-kosten-kortdurend-verblijf-en-de-spelregels\/. (accessed on: Oct 27, 2021)"},{"key":"903_CR22","unstructured":"AMC AUL. Nederlands Referentie Laboratorium voor Bacteri\u00eble Meningitis (NRLBM) 2021. Available from: https:\/\/www.amc.nl\/web\/specialismen\/medische-microbiologie-infectiepreventie-1\/medische-microbiologie-infectiepreventie-1\/nederlands-referentie-laboratorium-voor-bacteriele-meningitis-nrlbm.htm. (accessed on: Jan 25, 2022)"},{"key":"903_CR23","unstructured":"Regeling aanvullende bekostiging eduVIP2021. Available from: https:\/\/www.eduvip.nl\/regeling-aanvullende-bekostiging\/. (accessed on: Oct 27, 2021)"},{"key":"903_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s40064-015-0978-7","volume":"4","author":"A van der Kolk","year":"2015","unstructured":"van der Kolk A, Bouwmans CA, Schawo SJ, Buitelaar JK, van Agthoven M, Hakkaart-van Roijen L. Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands. Springerplus. 2015;4:224.","journal-title":"Springerplus"},{"issue":"3","key":"903_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jiph.2015.10.016","volume":"9","author":"S B\u00e9nard","year":"2016","unstructured":"B\u00e9nard S, Wright C, Voisine J, Olivier CW, Gaudelus J. Lifetime cost of meningococcal disease in France: scenarios of severe meningitis and septicemia with purpura fulminans. J Infect Public Health. 2016;9(3):339\u201347.","journal-title":"J Infect Public Health"},{"issue":"6","key":"903_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40258-018-0416-4","volume":"16","author":"J Pike","year":"2018","unstructured":"Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16(6):765\u201378.","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"903_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/0277-9536(92)90131-9","volume":"34","author":"MA Koopmanschap","year":"1992","unstructured":"Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992;34(9):1005\u201310.","journal-title":"Soc Sci Med"},{"issue":"Suppl 1","key":"903_CR28","doi-asserted-by":"publisher","first-page":"i89","DOI":"10.1136\/ard.2009.117150","volume":"69","author":"WB van den Hout","year":"2010","unstructured":"van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89-91.","journal-title":"Ann Rheum Dis"},{"key":"903_CR29","unstructured":"Statline C. Income, consumption, wealth of households: key figures; National Accounts 2021. Available from: https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/en\/dataset\/84102ENG\/table. (accessed on: Oct 27, 2021)"},{"key":"903_CR30","unstructured":"CBS. Average age of first-time mothers up to 29.9 years (in Dutch: Leeftijd moeder bij eerste kind stijgt naar 29,9 jaar) 2019. Available from: https:\/\/www.cbs.nl\/nl-nl\/nieuws\/2019\/19\/leeftijd-moeder-bij-eerste-kind-stijgt-naar-29-9-jaar. (accessed on: Oct 26, 2021)"},{"issue":"1","key":"903_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91\u2013104.","journal-title":"Value Health"},{"key":"903_CR32","unstructured":"Volksgezondheidenzorg.info. Participation. Figures&Context. Labour Participation [in Dutch: Participatie. Cijfers&Context. Arbeidsparticipatie] 2021. Available from: https:\/\/www.volksgezondheidenzorg.info\/onderwerp\/participatie\/cijfers-context\/arbeidsparticipatie#node-gezondheid-en-arbeidsparticipatie. (accessed on: Oct 26, 2021)"},{"issue":"6","key":"903_CR33","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","volume":"3","author":"AB Brueggemann","year":"2021","unstructured":"Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et\u00a0al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digital Health. 2021;3(6):e360\u201370.","journal-title":"Lancet Digital Health."},{"issue":"9","key":"903_CR34","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.3201\/eid2709.204866","volume":"27","author":"S Subbarao","year":"2021","unstructured":"Subbarao S, Campbell H, Ribeiro S, et\u00a0al. Invasive meningococcal disease, 2011\u20132020, and impact of the COVID-19 Pandemic, England. Emerg Infect Dis. 2021;27(9):2495\u20137.","journal-title":"Emerg Infect Dis"},{"key":"903_CR35","doi-asserted-by":"crossref","unstructured":"Clark S, Campbell H, Mensah AA, et\u00a0al. An increase in Group B invasive meningococcal disease among adolescents and young adults in England following easing of COVID-19 containment measures. SSRN. 2021.","DOI":"10.2139\/ssrn.3998164"},{"issue":"5","key":"903_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065036","volume":"8","author":"H Hepkema","year":"2013","unstructured":"Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W(1)(3)(5) and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS\u00a0One. 2013;8(5): e65036.","journal-title":"PLoS\u00a0One"},{"key":"903_CR37","unstructured":"Statistics Netherlands (Centraal Bureau voor de Statistiek). Vacancies (Vacatures) 2022. Available from: https:\/\/www.cbs.nl\/nl-nl\/visualisaties\/dashboard-arbeidsmarkt\/vacatures. (accessed on: Jan 25, 2022)"},{"key":"903_CR38","unstructured":"Statistics Netherlands (Centraal Bureau voor de Statistiek). Unemployed (Werklozen) 2022. Available from: https:\/\/www.cbs.nl\/nl-nl\/visualisaties\/dashboard-arbeidsmarkt\/werklozen. (accessed on: Jan 25, 2022)"},{"key":"903_CR39","unstructured":"Raad S-E. Werk: van belang voor iedereen. Een advies over werken met een chronische ziekte 2016. Available from: https:\/\/www.ser.nl\/-\/media\/ser\/downloads\/adviezen\/2016\/werken-chronische-ziekte.pdf. (accessed on: Oct 26, 2021)"},{"issue":"16","key":"903_CR40","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1016\/j.vaccine.2023.03.017","volume":"41","author":"M Middeldorp","year":"2023","unstructured":"Middeldorp M, Steens A, Lagerweij G, et\u00a0al. The burden of invasive meningococcal disease in the Netherlands, 2011\u20132020. Vaccine. 2023;41(16):2664\u201370.","journal-title":"Vaccine"},{"issue":"9","key":"903_CR41","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","volume":"11","author":"RM Viner","year":"2012","unstructured":"Viner RM, Booy R, Johnson H, et\u00a0al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774\u201383.","journal-title":"Lancet Neurol"},{"issue":"1","key":"903_CR42","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","volume":"32","author":"JA Bettinger","year":"2013","unstructured":"Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20\u20135.","journal-title":"Pediatr Infect Dis J"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00903-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00903-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00903-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T06:06:55Z","timestamp":1711519615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00903-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["903"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00903-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joost J. M. Simons and Tjalke A. Westra are employed by and hold shares in GSK. Florian Zeevat reports grants from GSK for the conduct of the study via her institution (UMCG\/RUG). Florian Zeevat also reports a grant from Health-Ecore and travel fees from GSK, outside the submitted work. Jan C. Wilschut reports consulting fees for advisory boards from Sanofi Pasteur and Janssen and payment from GSK for report writing outside the submitted work. Jan C. Wilschut also holds shares in Arbutus Corporation, Mymetics Corporation and ViciniVax Holding. Nina M. van Sorge declares consulting fees for service directly paid to her institution from MSD, outside the submitted work. Nina M. van Sorge also declares grants from Dutch Health Counsel, NIH and Amsterdam UMC and holds patent related to development of a vaccine against <i>Streptococcus pyogenes<\/i>, and for advisory board with the ItsME foundation (no honorarium) and the Rapua te me ngaro ka tau (honorarium paid to her institution), outside the submitted work. Nina M. van Sorge also holds share in Genmab BV. Cornelis Boersma reports funding from GSK to complete the work disclosed in this manuscript. Cornelis Boersma also receives consulting fees, payment and travel fees paid to his institution from various medical and pharmaceutical companies and has board membership with Netherlands Antibiotic Development Platform, ParkinsonNL, Veroz, Sustainable Health Accelerator and WAAH! Accelerator. Cornelis Boersma also holds shares in Health-Ecore, Digital Health Link, SensUR Health and Pitts. Maarten J. Postma holds shares in Health-Ecore and Pharmacoeconomics Advice Groningen Ltd. The authors declare no other financial and non-financial relationships and activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}